Philip Morris International Execs to Present at CAGNY 2026 Amid Smoke-Free Transition
Event summary
- Philip Morris International (PMI) will present at the CAGNY Conference on February 18, 2026, with CEO Jacek Olczak and CFO Emmanuel Babeau.
- Smoke-free products accounted for 41.5% of PMI’s total net revenues in 2025, used by over 43 million consumers.
- PMI has invested $16 billion since 2008 to develop smoke-free alternatives, including IQOS and nicotine pouches.
- FDA authorized marketing for IQOS devices, General snus, and ZYN nicotine pouches in the U.S.
The big picture
PMI’s CAGNY presentation comes as the company pivots toward smoke-free alternatives, backed by regulatory approvals and significant R&D investment. The shift reflects broader industry trends toward harm reduction and diversification in consumer health products. With over $16 billion invested since 2008, PMI is positioning itself at the forefront of a tobacco-free future, though execution risks remain.
What we're watching
- Regulatory Tailwinds
- How FDA approvals will accelerate PMI’s smoke-free product adoption in the U.S.
- Revenue Transition
- Whether PMI can sustain 41.5% revenue share from smoke-free products amid global market shifts
- Portfolio Expansion
- The pace at which PMI diversifies into wellness areas beyond tobacco and nicotine